BIONOR PHARMA AS NK -,10

Balance sheet

Assets 42,000,000  EUR 122,000,000  EUR 120,000,000  EUR 121,000,000  EUR
Goodwill 9,000,000  EUR 9,000,000  EUR 9,000,000  EUR 9,000,000  EUR
Current Assets 33,000,000  EUR 113,000,000  EUR 111,000,000  EUR 112,000,000  EUR
Cash And Cash Equivalents 11,000,000  EUR 93,000,000  EUR 108,000,000  EUR 109,000,000  EUR
Net Receivables 22,000,000  EUR 20,000,000  EUR 3,000,000  EUR 3,000,000  EUR
Liabilities 385,000,000  EUR 389,000,000  EUR 348,000,000  EUR 284,000,000  EUR
Equity 334,000,000  EUR 332,000,000  EUR 283,000,000  EUR 211,000,000  EUR
Common Stock 334,000,000  EUR 332,000,000  EUR 283,000,000  EUR 211,000,000  EUR
Current Liabilities 17,000,000  EUR 15,000,000  EUR 15,000,000  EUR 14,000,000  EUR
Accounts Payable 5,000,000  EUR 4,000,000  EUR 5,000,000  EUR 5,000,000  EUR
Short/Current Long Term Debt 0  EUR 0  EUR 0  EUR 3,000,000  EUR
Other Current Liabilities 12,000,000  EUR 11,000,000  EUR 10,000,000  EUR 6,000,000  EUR
Deferred Long Term Liability Charges 34,000,000  EUR 42,000,000  EUR 50,000,000  EUR 59,000,000  EUR

Key figures

On 31/12/15 the equity of company BIONOR PHARMA AS NK -,10 was 334,000,000 EUR.  As its assets have been 42,000,000 EUR the equity ratio is 795.23 %.  As the equity ratio is very high, the risk of selective default is lower than average. An investment in bonds of this company can be recommended, though first a deeper analysis of the current financial situation of BIONOR PHARMA AS NK -,10 should take place.

NO0003106700: SOLON EIENDOM ASA NK 1
The book value per share of SOLON EIENDOM ASA NK 1 (ISIN: NO0003106700) is 0. Current market price is 266.0000 Euro. As the current market price is higher than the book value per share, this financial instrument might not be a promising investment. Please check whether there are other factors like goodwill that justify this valuation.

Ticker Symbols

0MSG.L

BIONOR.OL

BIONORO.ST

BNRPF

NU5.F

NU5.SG